Venclexta (venetoclax; AbbVie/Roche) Drug Overview & Product Profile 2017-2026: A Novel B-Cell Lymphoma 2 (BCL-2) Inhibitor that Received an Accelerated US FDA Approval

[In The News]

DUBLIN, July 9, 2019 /PRNewswire/ -- The "Venclexta" report has been added to ResearchAndMarkets.com's offering. Drug Overview Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the...

View the full article